How to Get Jardiance in South Dakota

What Is Jardiance and Why Clinicians Prescribe It

Empagliflozin belongs to the sodium-glucose cotransporter-2 (SGLT2) inhibitor drug class. It blocks glucose reabsorption in the proximal tubule of the kidney, causing excess glucose to be excreted in urine. The FDA first approved Jardiance in August 2014 for adults with type 2 diabetes, later expanding the label to heart failure and chronic kidney disease (CKD). Refer to the current prescribing information for full label details.

The cardiovascular evidence base is substantial. The EMPA-REG OUTCOME trial (N=7,020 adults with type 2 diabetes and established cardiovascular disease) showed empagliflozin 10 mg or 25 mg reduced the composite of cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke by 14% versus placebo (hazard ratio 0.86; 95% CI 0.74 to 0.99; P<0.001 for non-inferiority, P=0.04 for superiority) over a median follow-up of 3.1 years. [1] Cardiovascular death was reduced by 38% (HR 0.62; 95% CI 0.49 to 0.77; P<0.001). [1]

In the EMPEROR-Reduced trial (N=3,730 patients with heart failure with reduced ejection fraction, EF <40%), empagliflozin 10 mg daily cut the primary endpoint of cardiovascular death or heart-failure hospitalization by 25% versus placebo (HR 0.75; 95% CI 0.65 to 0.86; P<0.001). [2] The FDA subsequently approved Jardiance for heart failure with reduced ejection fraction in 2021 and for heart failure with preserved ejection fraction after EMPEROR-Preserved data in 2022. [3]

For CKD, the EMPA-KIDNEY trial (N=6,609) demonstrated a 28% reduction in the risk of kidney disease progression or cardiovascular death (HR 0.72; 95% CI 0.64 to 0.82; P<0.001) in patients with eGFR 20 to 44 mL/min/1.73 m² or eGFR 45 to 90 mL/min/1.73 m² with a urine albumin-to-creatinine ratio of at least 200 mg/g. [4] The FDA approved Jardiance for CKD in 2023. [3]

The American Diabetes Association (ADA) 2024 Standards of Care recommend SGLT2 inhibitors as preferred add-on therapy for adults with type 2 diabetes and established cardiovascular disease, heart failure, or CKD regardless of HbA1c, based on cardiorenal outcome data. [5]

How to Get a Jardiance Prescription in South Dakota

Most South Dakota patients reach a valid Jardiance prescription through one of three pathways: an in-person visit with a primary care clinician, an endocrinologist or cardiologist referral, or a synchronous telehealth consultation. South Dakota law permits telehealth prescribing of Schedule-exempt medications, and empagliflozin is non-controlled, so no special waiver is needed.

Step 1. Choose a prescribing pathway. In-person visits at a primary care clinic, a Federally Qualified Health Center (FQHC), or an endocrinology practice remain the most common route. Telehealth platforms licensed in South Dakota can conduct a live video or phone consultation, review uploaded lab results, and send an electronic prescription to any South Dakota-licensed pharmacy the same day.

Step 2. Complete required pre-prescription labs. Before writing the prescription, clinicians check kidney function because empagliflozin's glucose-lowering effect diminishes significantly below an eGFR of approximately 30 mL/min/1.73 m², and the drug is generally not used for glycemic control at eGFR <30. [6] Standard pre-authorization labs include:

• Comprehensive metabolic panel (CMP) including serum creatinine and calculated eGFR
• HbA1c (diabetes indication)
• Urinalysis with urine albumin-to-creatinine ratio
• Blood pressure reading
• Body weight and BMI

Most commercial labs in South Dakota (Sanford Health labs, Avera lab network, Quest Diagnostics locations) return basic metabolic results within 24 to 48 hours. [7]

Step 3. Confirm insurance or explore cash-pay pricing. Jardiance's retail cash price ranges from approximately $580 to $640 per 30-tablet supply (10 mg or 25 mg) at South Dakota retail pharmacies as of mid-2025. Boehringer Ingelheim's Jardiance Savings Card can reduce out-of-pocket costs to as low as $10 per month for eligible commercially insured patients. [8] GoodRx coupons may bring cash-pay prices below $500 at select pharmacies, but this varies by location within SD.

Step 4. Submit the prescription and track dispensing. Electronic prescriptions (e-prescribing) go directly to the patient's chosen pharmacy. Mail-order pharmacies typically ship within 2 to 5 business days of insurance adjudication. Retail pharmacies in Sioux Falls, Rapid City, Aberdeen, and Watertown generally stock both 10 mg and 25 mg tablets.

Telehealth Prescribing of Jardiance in South Dakota

South Dakota explicitly permits telehealth prescribing for non-controlled medications without requiring a prior in-person examination, provided the clinician conducts a real-time audio-visual evaluation and documents a valid patient-physician relationship. [9] This means a patient in rural Mobridge or Winner can obtain a Jardiance prescription without driving to Sioux Falls.

HealthRX Telehealth Prescribing Pathway for Empagliflozin in SD

The HealthRX clinical team uses the following decision framework for new empagliflozin telehealth consultations in South Dakota:

1. Eligibility screen (Day 0). Patient completes online intake with chief complaint, current medications, allergy history, and uploaded or lab-linked metabolic panel results.
2. Synchronous video visit (Day 0 or Day 1). Licensed South Dakota clinician reviews labs, confirms indication (type 2 diabetes, heart failure, or CKD), checks for contraindications (recurrent UTIs, history of DKA, active bladder cancer, dialysis dependence), and documents shared decision-making.
3. e-Prescription transmission (Day 1). Prescription is sent to patient's preferred pharmacy or a mail-order partner. Starting dose: 10 mg once daily with or without food.
4. Lab recheck at 4 weeks. Repeat eGFR and metabolic panel to confirm renal tolerability and electrolyte balance.
5. Dose titration at 12 weeks (diabetes indication). If HbA1c target is not met and eGFR remains above 45 mL/min/1.73 m², the clinician may increase to 25 mg once daily. [6]

The American Association of Clinical Endocrinology (AACE) 2022 Diabetes Management Algorithm states: "SGLT2 inhibitors are recommended preferentially for patients with type 2 diabetes who have established atherosclerotic cardiovascular disease, heart failure, or CKD." [10]

Who Can Prescribe Jardiance in South Dakota

South Dakota grants full prescriptive authority to multiple clinician types for non-controlled medications.

Medical doctors (MD) and doctors of osteopathic medicine (DO) hold unrestricted prescriptive authority. They may prescribe Jardiance for any FDA-approved indication or, at their clinical discretion, off-label.

Nurse practitioners (NP) in South Dakota practice under a reduced-practice model. NPs must have a collaborative agreement with a licensed physician. Within that agreement, NPs may independently prescribe Schedule-exempt medications including empagliflozin. [11]

Physician assistants (PA) operate under a supervisory agreement with a physician. PAs may prescribe Jardiance when the supervising physician's agreement covers the relevant clinical scope. [11]

Pharmacists in South Dakota do not currently hold independent prescriptive authority for SGLT2 inhibitors; they may, however, provide medication therapy management (MTM) services and collaborate on prior authorization documentation.

Required Labs Before Starting Jardiance

Pre-prescription laboratory testing is both a clinical necessity and a frequent prior-authorization requirement. The Jardiance prescribing information specifies that eGFR should be assessed before initiation. [6] Here is a complete checklist:

| Lab | Why It Matters | Threshold | |---|---|---| | Serum creatinine + eGFR | Dosing and safety | Do not initiate for glycemic control if eGFR <30 | | HbA1c | Baseline glycemic control (T2D indication) | Guides target-setting | | Urine albumin-to-creatinine ratio | CKD staging | Relevant to CKD indication approval | | Fasting glucose | Baseline and DKA risk context | Elevated in ketosis-prone patients | | Serum potassium | Hyperkalemia risk with concurrent ACE/ARB | Flag if >5.0 mEq/L | | Blood pressure | Orthostatic hypotension risk | Relevant with diuretics |

Sanford Health in Sioux Falls and Avera Health in Rapid City both offer fasting morning lab draws with same-day electronic results delivery, which allows telehealth clinicians to review results and issue prescriptions within 24 to 48 hours of the patient's blood draw. [7]

South Dakota Insurance Coverage and Prior Authorization

South Dakota Medicaid (administered through Wellcare and Anthem under the Medicaid managed care contract) does not currently list Jardiance on its preferred drug list for type 2 diabetes, heart failure, or CKD as of the 2025 formulary review cycle. Patients covered by Medicaid will generally need to use a formulary-preferred SGLT2 inhibitor if available, or document medical necessity through an exceptions process.

For commercial insurance plans, most South Dakota carriers (Sanford Health Plan, Avera Health Plans, Wellmark Blue Cross, and large national PBMs) require prior authorization. A successful prior authorization submission typically includes:

• Documented diagnosis code (ICD-10: E11.x for type 2 diabetes, I50.x for heart failure, N18.x for CKD)
• Current HbA1c or eGFR result within the past 6 months
• Trial and failure of or contraindication to a first-line agent (metformin for T2D; the plan may specify one or two agents)
• Prescribing clinician's attestation of cardiovascular, heart failure, or CKD comorbidity when applicable
• Patient weight and BMI

Prior authorization approval timelines in South Dakota generally run 3 to 10 business days for standard reviews and 24 to 72 hours for urgent clinical reviews. Some Wellmark plans approve SGLT2 inhibitors faster when documented CV disease or heart failure is on file.

The Boehringer Ingelheim patient assistance program (called "Lilly Insulin Value Program" is not applicable here; the correct program is Boehringer Ingelheim's "ingelheimCares") may cover costs for uninsured or underinsured South Dakota patients who meet income thresholds. [8]

Pharmacy Options in South Dakota

South Dakota retail and mail-order pharmacies are the primary dispensing channels for Jardiance.

Retail pharmacies with confirmed stock of both 10 mg and 25 mg empagliflozin tablets include:

• Walgreens locations in Sioux Falls, Rapid City, Aberdeen
• CVS Pharmacy in Sioux Falls
• Sanford Health Pharmacy (Sioux Falls and Fargo-region affiliates)
• Avera Pharmacy in Sioux Falls and Mitchell
• Walmart Pharmacy in multiple South Dakota cities

Mail-order pharmacies licensed to ship to South Dakota addresses include CVS Caremark, Express Scripts, OptumRx, and Amazon Pharmacy. Shipping to rural ZIP codes in western South Dakota typically adds 1 to 2 business days to the estimated delivery window.

503A compounding pharmacies licensed in South Dakota may prepare patient-specific compounded formulations of empagliflozin (for example, a liquid suspension for a patient with tablet-swallowing difficulty) when a licensed prescriber provides a valid individual prescription. Section 503A of the Federal Food, Drug, and Cosmetic Act requires that compounded preparations not be copies of commercially available products; clinicians must document a clinical rationale. [12] No 503B outsourcing facility currently lists empagliflozin on a bulk-compounding list, so 503B sourcing is not a current option for South Dakota patients.

Transferring an Existing Jardiance Prescription to South Dakota

Patients moving to South Dakota from another state can transfer an active Jardiance prescription to any South Dakota retail pharmacy using the standard pharmacy transfer process. Because empagliflozin is not a controlled substance, no DEA-transfer restriction applies. The receiving pharmacist contacts the originating pharmacy to verify the remaining refills and prescription date.

For mail-order prescriptions, the patient's plan PBM (Express Scripts, Caremark, OptumRx) can update the shipping address without requiring a new prescription, provided the original prescription has remaining refills. A new prior authorization may be required if the patient's insurance plan changes upon moving to South Dakota.

If the patient switches from a telehealth provider licensed only in the original state to a South Dakota-licensed provider, the new clinician can review records, document continuity of care, and write a new prescription in South Dakota. The 90-day supply written in the previous state does not automatically transfer as a valid South Dakota prescription if the issuing clinician is not licensed in SD.

Dosing, Titration, and Duration of Use

The FDA-approved starting dose for type 2 diabetes is empagliflozin 10 mg once daily, taken in the morning with or without food. [6] The dose may be increased to 25 mg once daily if additional glycemic control is needed and the patient tolerates the 10 mg dose. For heart failure and CKD indications, the approved dose is 10 mg once daily; dose escalation to 25 mg is not indicated for those conditions per current labeling. [6]

Empagliflozin is taken as a long-term daily medication. In EMPA-REG OUTCOME, benefit on cardiovascular outcomes continued to accrue over the full 3.1-year median follow-up. [1] Patients should not discontinue empagliflozin without consulting their clinician, as abrupt discontinuation in heart failure populations has been associated with rebound fluid retention in observational cohorts, though randomized discontinuation data are limited.

Hold empagliflozin at least 3 to 4 days before any major elective surgery or prolonged fasting to reduce the risk of euglycemic diabetic ketoacidosis (eDKA), a rare but serious adverse event documented in case series and the FDA's post-marketing surveillance database. [13] The FDA issued a Drug Safety Communication on this risk in 2015 and updated it in 2020. [13]

Side Effects and Safety Monitoring in South Dakota Patients

Common adverse effects include genital mycotic infections (candidal vulvovaginitis or balanitis), occurring in approximately 6 to 7% of patients versus 1 to 2% for placebo in pooled trial data. [14] Urinary tract infections are modestly increased. Volume depletion symptoms (dizziness, lightheadedness) occur more often in patients on loop diuretics; South Dakota clinicians managing concurrent furosemide therapy should check blood pressure and electrolytes within 4 weeks of starting empagliflozin. [6]

Fournier's gangrene (necrotizing fasciitis of the perineum) has been reported rarely across the SGLT2 inhibitor class; the FDA safety database identified 12 cases over approximately 6 years of post-marketing surveillance across all approved SGLT2 inhibitors. [15] Patients should be counseled to seek immediate care for perineal pain, swelling, or fever.

Bone fracture risk was not elevated in EMPA-REG OUTCOME (fracture rates: 4.1% empagliflozin vs. 4.3% placebo), distinguishing empagliflozin from canagliflozin, which carries an FDA boxed warning for fracture risk. [1]

Cost-Reduction Strategies for South Dakota Patients

For commercially insured patients, the Jardiance Savings Card (accessed at jardiance.com or through the prescribing clinician's office) caps monthly out-of-pocket to $10 per 30-day supply for eligible patients. [8]

For uninsured patients, three programs are available:

1. ingelheimCares (Boehringer Ingelheim patient assistance): Income-based free medication for qualifying uninsured patients. [8]
2. NeedyMeds database: Lists additional South Dakota-specific assistance programs.
3. GoodRx or Cost Plus Drugs (Mark Cuban): Retail cash pricing at Cost Plus Drugs for empagliflozin 10 mg (30 tablets) was approximately $480 as of early 2025, below the retail cash price at most chain pharmacies.

South Dakota does not have a state pharmaceutical assistance program (SPAP) for working-age adults, unlike states such as Delaware or Illinois that supplement Medicare Part D costs.